Durvalumab after sequential CRT safe in stage III, unresectable NSCLC Presented ByDr Marina Garassino, University of Chicago, IL, USA TrialPhase 2, PACIFIC-6 ConferenceELCC 2022 TypePeer-reviewed article 25 May 2022 12:37